http://www.genengnews.com/gen-news-...-drug-development-deal-with-servier/81245528/
Intercept $163M Diabetes Drug Development Deal with Servier
Intercept Pharmaceuticals could receive up to $163 million from Servier as part of a worldwide (excluding the U.S. and Japan) agreement centered on the discovery and development of TGR5 (GPR131) agonists for the treatment of type 2 diabetes and other metabolic indications. The partnership will exploit Intercept’s drug discovery platform, which is based on bile acid analog chemistry, and expertise in targeting TGR5 and other bile receptors.
Intercept $163M Diabetes Drug Development Deal with Servier
Intercept Pharmaceuticals could receive up to $163 million from Servier as part of a worldwide (excluding the U.S. and Japan) agreement centered on the discovery and development of TGR5 (GPR131) agonists for the treatment of type 2 diabetes and other metabolic indications. The partnership will exploit Intercept’s drug discovery platform, which is based on bile acid analog chemistry, and expertise in targeting TGR5 and other bile receptors.